| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | ||||||||
-14,911 | -8,275 | -9,018 | -8,471 | -7,204 | -7,075 | -4,887 | -3,026 | -4,282 |
Reconciliation of net loss to net cash used in operating activities | ||||||||
Depreciation and amortization | ||||||||
47 | -62 | 96 | 85 | 37 | - | - | - | - |
Stock-based compensation expense | ||||||||
776 | 654 | 776 | 1,030 | 682 | 133 | 890 | 740 | 1,319 |
Due to Parent under asset contribution agreement | ||||||||
- | - | - | - | 500 | - | - | - | 1,000 |
Changes in operating assets and liabilities: | ||||||||
Prepaid expenses and other assets | ||||||||
1,838 | 572 | -391 | -283 | 1,292 | 24 | -151 | -139 | 805 |
Accounts payable, accrued expenses and other | ||||||||
3,769 | 331 | 96 | 1,546 | 1,607 | 2,617 | 653 | -1,812 | 1,743 |
Due to related party | ||||||||
- | - | - | - | - | - | - | - | 13 |
Net cash used in operating activities | ||||||||
-12,157 | -7,924 | -7,659 | -6,027 | -5,670 | -4,341 | -3,186 | -4,970 | -1,012 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchases of equipment and leasehold improvements | ||||||||
16 | - | - | - | 600 | - | - | - | - |
Net cash used in investing activities | ||||||||
-16 | -2 | -43 | -225 | -600 | - | - | - | - |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from issuance of common stock, net of issuance costs | ||||||||
68,811 | - | - | - | - | 1 | 0 | 0 | 56,512 |
Purchase and cancellation of shares from BioXcel Corporation | ||||||||
9,024 | - | - | - | - | - | - | - | - |
Exercise of options | ||||||||
39 | - | - | - | 1 | - | - | - | - |
Due to Parent | ||||||||
- | - | - | - | - | 1 | 21 | -26 | -551 |
Note Payable — Parent | ||||||||
- | - | - | - | - | 0 | 0 | 0 | -371 |
Net cash provided by financing activities | ||||||||
59,826 | 100 | 17,989 | -79 | 1 | -58 | 21 | -26 | 55,590 |
Net (decrease) increase in cash and cash equivalents | ||||||||
47,653 | -7,826 | 10,287 | -6,331 | -6,269 | -4,557 | -3,227 | -5,116 | 54,578 |
Supplemental cash flow information: | ||||||||
Interest paid | ||||||||
3 | 15 | 18 | 21 | 8 | 0 | 0 | -1 | 2 |
Supplemental disclosure of non-cash Operating, Investing and Financing Activities: | ||||||||
Deferred issuance costs, unpaid as of December 31, 2017 | ||||||||
- | - | - | - | - | - | 0 | 0 | 391 |
Deferred issuance costs reclassified to additional paid-in-capital upon completion of initial public offering | ||||||||
- | - | - | - | - | 0 | 0 | 0 | 461 |
Reclassification of net Parent Investment in the Company to accumulated deficit. | ||||||||
- | - | - | - | - | - | 0 | 0 | 440 |